

Progetto **CANOA**  
**CARCINOMA  
MAMMARIO:**

QUALI NOVITA' PER IL 2016?

"Saper leggere" uno studio clinico per migliorare la pratica clinica

Coordinatori scientifici:  
Stefania Gori  
Giovanni L. Pappagallo



Ospedaletto di Pescantina (VR) 22-23 Aprile 2016  
Villa Quaranta Park Hotel

**QUESITO GRADE: nelle pazienti con carcinoma mammario HER-2 + metastatico senza metastasi viscerali, l'aggiunta del Pertuzumab al Trastuzumab + taxano è raccomandabile rispetto al Trastuzumab + taxano?**

**Discussione sulla qualità e sulla rilevanza clinica delle evidenze**

Dott.ssa ELENA FIORIO AOUI Verona

**Author(s):**

**Date:**

**Question:** Pertuzumab compared to Trastuzumab for 1a linea MBC HER2+

**Setting:** malattia non viscerale

**Bibliography:**

Quality assessment							N° of patients		Effect		Quality	Importance
N° of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Pertuzumab	Trastuzumab	Relative (95% CI)	Absolute (95% CI)		
OS (follow up: median 50 months; assessed with: KM)												
1	randomised trials	not serious	not serious	not serious	very serious <sup>1</sup>	none	30/88 (34.1%)	28/90 (31.1%)	<b>HR 1.11</b> (0.66 to 1.85)	<b>3 more per 100</b> (from 9 fewer to 19 more) 4	⊕⊕○○ LOW	CRITICO
PFS (follow up: median 50 months; assessed with: KM)												
1	randomised trials	not serious	not serious	not serious	serious <sup>2</sup>	none	-/88	-/90	<b>HR 0.83</b> (0.58 to 1.18)	<b>-- per 100</b> (from -- to --)	⊕⊕⊕○ MODERATE	CRITICO
Cardiotox (assessed with: CTC-AE)												
1	randomised trials	not serious	not serious	serious	not serious <sup>3</sup>	none	27/408 (6.6%)	34/396 (8.6%)	<b>RR 0.785</b> (0.482 to 1.278)	<b>2 fewer per 100</b> (from 2 more to 4 fewer)	⊕⊕⊕○ MODERATE	CRITICO
Tox. limitante												
1	randomised trials	not serious	not serious	serious <sup>4</sup>	not serious <sup>3</sup>	none	31/397 (7.8%)	30/407 (7.4%)	<b>RR 1.057</b> (0.652 to 1.716)	<b>0 fewer per 100</b> (from 3 fewer to 5 more)	⊕⊕⊕○ MODERATE	CRITICO

**CI:** Confidence interval; **HR:** Hazard Ratio; **RR:** Risk ratio

1. LC95% compatibili con conclusioni cliniche di segno opposto (-2)
2. LC95% compatibili con conclusioni cliniche di segno opposto (-1)
3. Non downgrade per imprecisione, data la bassa incidenza dell'AE
4. No explanation was provided